Ozempic vs Zepbound: Different Molecules, Different Approved Uses

They are different molecules with different FDA-approved indications: Ozempic (semaglutide) for type 2 diabetes and Zepbound (tirzepatide) for chronic weight management. Ozempic acts on the GLP-1 receptor; Zepbound acts on both the GIP and GLP-1 receptors. Which one is appropriate for a given person is a clinical decision made by a licensed provider based on their individual medical profile.

No, you should not take both simultaneously. They are both incretin-based receptor agonists, and combining them would increase the risk of side effects without established additional benefit. A licensed provider will determine the appropriate single medication based on your health profile and treatment goals.

Both have similar gastrointestinal side effects — nausea, vomiting, diarrhea, and constipation are the most common. Individual responses vary, and side effects for both tend to improve after the initial dose escalation period. A licensed provider evaluates tolerability for each patient.

Any change between medications requires medical supervision, and Weight Method dispenses neither brand-name product. Whether a transition is appropriate and how dosing is managed is determined by a licensed provider based on your goals and individual medical profile. Discuss your options during a Weight Method consultation.

They belong to the same broad incretin-based class but are different molecules. Semaglutide acts on the GLP-1 receptor, while tirzepatide acts on both the GLP-1 and GIP receptors. Ozempic is a semaglutide product and Zepbound is a tirzepatide product. Whether either molecule is appropriate for an individual is determined by a licensed provider.